StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report published on Saturday morning. The brokerage issued a sell rating on the medical technology company’s stock.
Other analysts also recently issued reports about the stock. Ascendiant Capital Markets cut their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Wednesday, October 2nd.
Get Our Latest Stock Analysis on BIOL
BIOLASE Stock Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share for the quarter. The firm had revenue of $11.56 million during the quarter. BIOLASE had a negative net margin of 41.65% and a negative return on equity of 1,782.73%.
Hedge Funds Weigh In On BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC increased its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by institutional investors.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Read More
- Five stocks we like better than BIOLASE
- Best Stocks Under $5.00
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How is Compound Interest Calculated?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.